Effects of varenicline on smoking cessation in patients with mild to moderate COPD

A randomized controlled trial

Donald P. Tashkin, Stephen Israel Rennard, J. Taylor Hays, Wendy Ma, David Lawrence, Theodore C. Lee

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Background: Smoking is the most important risk factor for COPD and accelerates its progression. Despite the health implications, a large proportion of patients with COPD continue to smoke, so finding effective smoking cessation interventions for this population is paramount. To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD. Methods: In a 27-center, double-blind, multinational study, 504 patients with mild to moderate COPD (postbronchodilator FEV1/FVC, <70%; FEV1 percent predicted normal value, ≥50%) and without known psychiatric disturbances were randomized to receive varenicline (n = 250) or placebo (n = 254) for 12 weeks, with a 40-week nontreatment follow-up. The primary end point was carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12. A secondary end point was CAR for weeks 9 to 52. Results: CAR for weeks 9 to 12 was significantly higher for patients in the varenicline group (42.3%) than for those in the placebo group (8.8%) (OR, 8.40; 95% CI, 4.99-14.14; P<.0001). CAR in the patients treated with varenicline remained significantly higher than in those treated with placebo through weeks 9 to 52(18.6% vs 5.6%) (OR, 4.04; 95% CI, 2.13-7.67; P<.0001). Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia were the most commonly reported adverse events (AEs) for patients in the varenicline group. Serious AEs were infrequent in both treatment groups. Two patients in the varenicline group and one patient in the placebo group died during the study. Reports of psychiatric AEs were similar for both treatment groups. Conclusions: Varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate COPD and demonstrated a safety profile consistent with that observed in previous trials. Trial registry: ClinicalTrials.gov; No.: NCT00285012; URL:www.clinicaltrials.gov.

Original languageEnglish (US)
Pages (from-to)591-599
Number of pages9
JournalChest
Volume139
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Smoking Cessation
Chronic Obstructive Pulmonary Disease
Randomized Controlled Trials
Placebos
Psychiatry
Safety
Varenicline
Sleep Initiation and Maintenance Disorders
Carbon Monoxide
Double-Blind Method
Smoke
Respiratory Tract Infections
Nausea
Registries
Reference Values
Smoking
Health
Therapeutics
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Tashkin, D. P., Rennard, S. I., Hays, J. T., Ma, W., Lawrence, D., & Lee, T. C. (2011). Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest, 139(3), 591-599. https://doi.org/10.1378/chest.10-0865

Effects of varenicline on smoking cessation in patients with mild to moderate COPD : A randomized controlled trial. / Tashkin, Donald P.; Rennard, Stephen Israel; Hays, J. Taylor; Ma, Wendy; Lawrence, David; Lee, Theodore C.

In: Chest, Vol. 139, No. 3, 01.03.2011, p. 591-599.

Research output: Contribution to journalArticle

Tashkin, DP, Rennard, SI, Hays, JT, Ma, W, Lawrence, D & Lee, TC 2011, 'Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial', Chest, vol. 139, no. 3, pp. 591-599. https://doi.org/10.1378/chest.10-0865
Tashkin, Donald P. ; Rennard, Stephen Israel ; Hays, J. Taylor ; Ma, Wendy ; Lawrence, David ; Lee, Theodore C. / Effects of varenicline on smoking cessation in patients with mild to moderate COPD : A randomized controlled trial. In: Chest. 2011 ; Vol. 139, No. 3. pp. 591-599.
@article{ba8d177faa414ebf9691a11d1bb4b182,
title = "Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial",
abstract = "Background: Smoking is the most important risk factor for COPD and accelerates its progression. Despite the health implications, a large proportion of patients with COPD continue to smoke, so finding effective smoking cessation interventions for this population is paramount. To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD. Methods: In a 27-center, double-blind, multinational study, 504 patients with mild to moderate COPD (postbronchodilator FEV1/FVC, <70{\%}; FEV1 percent predicted normal value, ≥50{\%}) and without known psychiatric disturbances were randomized to receive varenicline (n = 250) or placebo (n = 254) for 12 weeks, with a 40-week nontreatment follow-up. The primary end point was carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12. A secondary end point was CAR for weeks 9 to 52. Results: CAR for weeks 9 to 12 was significantly higher for patients in the varenicline group (42.3{\%}) than for those in the placebo group (8.8{\%}) (OR, 8.40; 95{\%} CI, 4.99-14.14; P<.0001). CAR in the patients treated with varenicline remained significantly higher than in those treated with placebo through weeks 9 to 52(18.6{\%} vs 5.6{\%}) (OR, 4.04; 95{\%} CI, 2.13-7.67; P<.0001). Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia were the most commonly reported adverse events (AEs) for patients in the varenicline group. Serious AEs were infrequent in both treatment groups. Two patients in the varenicline group and one patient in the placebo group died during the study. Reports of psychiatric AEs were similar for both treatment groups. Conclusions: Varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate COPD and demonstrated a safety profile consistent with that observed in previous trials. Trial registry: ClinicalTrials.gov; No.: NCT00285012; URL:www.clinicaltrials.gov.",
author = "Tashkin, {Donald P.} and Rennard, {Stephen Israel} and Hays, {J. Taylor} and Wendy Ma and David Lawrence and Lee, {Theodore C.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1378/chest.10-0865",
language = "English (US)",
volume = "139",
pages = "591--599",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Effects of varenicline on smoking cessation in patients with mild to moderate COPD

T2 - A randomized controlled trial

AU - Tashkin, Donald P.

AU - Rennard, Stephen Israel

AU - Hays, J. Taylor

AU - Ma, Wendy

AU - Lawrence, David

AU - Lee, Theodore C.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Smoking is the most important risk factor for COPD and accelerates its progression. Despite the health implications, a large proportion of patients with COPD continue to smoke, so finding effective smoking cessation interventions for this population is paramount. To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD. Methods: In a 27-center, double-blind, multinational study, 504 patients with mild to moderate COPD (postbronchodilator FEV1/FVC, <70%; FEV1 percent predicted normal value, ≥50%) and without known psychiatric disturbances were randomized to receive varenicline (n = 250) or placebo (n = 254) for 12 weeks, with a 40-week nontreatment follow-up. The primary end point was carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12. A secondary end point was CAR for weeks 9 to 52. Results: CAR for weeks 9 to 12 was significantly higher for patients in the varenicline group (42.3%) than for those in the placebo group (8.8%) (OR, 8.40; 95% CI, 4.99-14.14; P<.0001). CAR in the patients treated with varenicline remained significantly higher than in those treated with placebo through weeks 9 to 52(18.6% vs 5.6%) (OR, 4.04; 95% CI, 2.13-7.67; P<.0001). Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia were the most commonly reported adverse events (AEs) for patients in the varenicline group. Serious AEs were infrequent in both treatment groups. Two patients in the varenicline group and one patient in the placebo group died during the study. Reports of psychiatric AEs were similar for both treatment groups. Conclusions: Varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate COPD and demonstrated a safety profile consistent with that observed in previous trials. Trial registry: ClinicalTrials.gov; No.: NCT00285012; URL:www.clinicaltrials.gov.

AB - Background: Smoking is the most important risk factor for COPD and accelerates its progression. Despite the health implications, a large proportion of patients with COPD continue to smoke, so finding effective smoking cessation interventions for this population is paramount. To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD. Methods: In a 27-center, double-blind, multinational study, 504 patients with mild to moderate COPD (postbronchodilator FEV1/FVC, <70%; FEV1 percent predicted normal value, ≥50%) and without known psychiatric disturbances were randomized to receive varenicline (n = 250) or placebo (n = 254) for 12 weeks, with a 40-week nontreatment follow-up. The primary end point was carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12. A secondary end point was CAR for weeks 9 to 52. Results: CAR for weeks 9 to 12 was significantly higher for patients in the varenicline group (42.3%) than for those in the placebo group (8.8%) (OR, 8.40; 95% CI, 4.99-14.14; P<.0001). CAR in the patients treated with varenicline remained significantly higher than in those treated with placebo through weeks 9 to 52(18.6% vs 5.6%) (OR, 4.04; 95% CI, 2.13-7.67; P<.0001). Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia were the most commonly reported adverse events (AEs) for patients in the varenicline group. Serious AEs were infrequent in both treatment groups. Two patients in the varenicline group and one patient in the placebo group died during the study. Reports of psychiatric AEs were similar for both treatment groups. Conclusions: Varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate COPD and demonstrated a safety profile consistent with that observed in previous trials. Trial registry: ClinicalTrials.gov; No.: NCT00285012; URL:www.clinicaltrials.gov.

UR - http://www.scopus.com/inward/record.url?scp=79952222942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952222942&partnerID=8YFLogxK

U2 - 10.1378/chest.10-0865

DO - 10.1378/chest.10-0865

M3 - Article

VL - 139

SP - 591

EP - 599

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -